Short Communication

Asymptomatic Neurosyphilis in HIV infected patients at a Brazilian HIV and AIDS specialized service: a cross sectional study

Cláudio Queniti Hirai\(^{[1]}\), Deborah de Castro Moreira\(^{[1]}\), Danielle Cristina Tita Granzotto\(^{[2]}\), Eniuce Menezes de Souza\(^{[2]}\), Jorge Juarez Vieira Teixeira\(^{[3]}\) and Dennis Armando Bertolini\(^{[3]}\)

\(^{[1]}\) Universidade Estadual de Maringá, Programa de Pós-Graduação em Ciências da Saúde, Maringá, PR, Brasil.
\(^{[2]}\) Universidade Estadual de Maringá, Departamento de Estatística, Maringá, PR, Brasil.
\(^{[3]}\) Universidade Estadual de Maringá, Departamento de Análises Clínicas e Biomedicina, Maringá, PR, Brasil.

ABSTRACT

**Background:** Many human immunodeficiency virus (HIV) and syphilis co-infected patients are not diagnosed, which may evolve into asymptomatic neurosyphilis (ANS). We studied the occurrence of ANS in an HIV-infected population.

**Methods:** This was a cross-sectional study of cerebrospinal fluid (CSF) samples collected from patients co-infected with HIV and *Treponema pallidum*. Social-demographic and clinical-laboratory characteristics were studied.

**Results:** Of the 348 patients infected with HIV, 33 (9.5%) had reagent treponemic and non-treponemic tests. CSF was collected from 19 asymptomatic patients. Of these, 8 (42.1%) presented with laboratory alterations suggestive of ANS.

**Conclusion:** Social-demographic and clinical-laboratory variables should be considered for the indication of CSF collection.

**Keywords:** HIV. Acquired Immunodeficiency Syndrome. Neurosyphilis. Co-infection. Syphilis.

Globally, more than one million sexually transmitted infections (STIs) occur daily\(^{[1]}\). The prevailing STIs are chlamydia, gonorrhea, trichomoniasis, and syphilis, corresponding to 33.8%, 23.1%, 41.5%, and 1.7%, respectively\(^{[1]}\). Despite its low percentage, when compared to other STIs, syphilis can evolve into chronic and asymptomatic forms, leading to an expansion of its propagation. It is worth mentioning that syphilis infection greatly increases the transmission and acquisition of HIV\(^{[1]}\).

Syphilis is the most common STI among patients with HIV infection\(^{[2]}\), with a median of 9.5% in developed and developing countries\(^{[3]}\). Studies have shown different prevalence rates of asymptomatic neurosyphilis (ANS) in patients co-infected with HIV and syphilis. Rotman et al. retrospectively studied 230 patients with cerebrospinal fluid (CSF) analysis for 10 years in American hospitals and found 70 (8.57%) ANS cases\(^{[4]}\).

Lumbar puncture is recommended in patients with clinical evidence of neurological involvement, such as cognitive dysfunction, motor or sensory deficits, ophthalmological or auditory symptoms, cranial nerve palsy and meningitis or stroke signs or symptoms, tertiary syphilis with cardiovascular or gum disease signs or symptoms, and in cases of treatment failure\(^{[5]}\). CSF abnormalities are often associated with a CD4 + T lymphocyte count (CD4TL) ≤ 350 cells/mm³ and/or a Venereal Disease Research Laboratory (VDRL) titer ≥ 1:32\(^{[5]}\).

\(^{[1]}\) in memorian.

**Corresponding author:** Dr. Dennis Armando Bertolini. E-mail: dabertolini@uem.br

**Author’s contribution:** CQH: Conception and design of the study, Acquisition of data, Analysis and interpretation of data, Drafting the article; DCM: Drafting the article, Final approval of the version to be submitted; DCTG: (in memorian) Analysis and interpretation of data, Final approval of the version to be submitted; EMS: Analysis and interpretation of data, Final approval of the version to be submitted; JJVT: Conception and design of the study, Analysis and interpretation of data, Final approval of the version to be submitted; DAB: Conception and design of the study, Analysis and interpretation of data, Final approval of the version to be submitted.

**Conflict of Interest:** The authors declare that there is no conflict of interest in the development of this study.
Polymerase chain reaction (PCR) and dark field microscopy are the gold standard techniques for mucocutaneous lesions; however, in CSF, they have low sensitivity when compared to serological assays. Thus, CSF serological assays have been the mainstay of diagnosis for neurosyphilis. In CSF, VDRL has good specificity but limited sensitivity; however, it is still considered the gold standard assay. A reactive CSF-VDR test confirmed the diagnosis of neurosyphilis, but a negative test does not exclude it.

In Brazil, as neurosyphilis has not been reported, there are few epidemiological data, especially on its asymptomatic form. The aim of this study was to analyze the frequency and characteristics of ANS in an HIV-infected population, followed by an HIV/AIDS reference clinic.

We conducted a cross-sectional study with consecutive sampling according to the following inclusion criteria: patients HIV-infected with serological treponemic and non-treponemal test reagents for syphilis; fully asymptomatic; older than 16 years; not pregnant; with recent viral load and CD4LT count examinations; without diseases that justified liquor alterations, without neurological, ophthalmological, otological, or tertiary syphilis signs or symptoms; increase or maintenance of VDRL titers, compared to the previous syphilis exam; latent syphilis independent of previous treatment for syphilis; and CD4LT count and/or VDRL serological titer.

People living with HIV/AIDS (PLHIV) in this study were clinically attended between October 1, 2018, and September 30, 2019, in the Specialized HIV and AIDS Assistance Service (SAE) of the Inter-municipalities Health Consortium of the North of Paraná, a reference clinic for 21 municipalities, with 224,721 habitants, located in the city of Cornélia Procópio, State of Paraná. Selected patients underwent CSF collection at Cornélia Procópio’s House of Mercy Hospital. Blood and CSF examinations were performed in the reference laboratories of the Brazilian Unified Health System.

The following liquor characteristics were considered as neurosyphilis: VDRL at any title, or/and leukocyte count (pleocytosis) higher than 20 cells/mm³, and/or a protein increase over 40 mg/dL. A questionnaire was administered to patients for clinical-epidemiological and social-demographical data collection. Patient date on previous diagnoses, treatment, and follow-up were gathered from clinical records. The following definitions were applied: (a) adequate treatment, patients with treatment and laboratory monitoring; (b) inadequate treatment, patients with inadequate treatment or laboratory monitoring; and (c) lack of syphilis treatment, patients without previous treatment history.

The frequency distribution of the clinical-epidemiological and social-demographic variables were analyzed. Non-parametric statistical tests were applied, such as the chi-square test of independence. Statistical analysis was conducted using R software, version 3.5.3. The Ethics Committee of the State University of Maringá approved the project (CAAE 13174419.3.0000.0104; Protocol no. 3.390.519), in compliance with the guidelines and regulatory requirements for human research. All participants who agreed to participate signed an informed consent form.

During the study period, from the 393 patients with HIV infection attended by SAE, 348 were tested for syphilis, of which 73 (21%) presented treponemal test reagents to syphilis. Of these, 31 (42.5%) were considered cured after adequate treatment and a follow-up with negative VDRL, 9 (12.3%) lost clinical follow-up, and 33 (45.2%) had treponemal and non-treponemal test reagents for syphilis. From the 33 patients, target of this study, 19 (57.6%) patients collected the CSF sample (Figure 1). The majority were male (73.7%), white (52.6%), single (52.6%), and aged between 20 and 49 years (73.7%).

Retrospective analysis of medical records of the 19 patients (Supplementary Table 1) indicated that 15 (78.9%) had a previous history of syphilis treatment, of which 8 (53.3%) had serum VDRL titers ≥1:32, and 9 (60%) with an CD4LT count lower than 350 cells/mm³ at the time of their diagnosis, which could suggest CSF collection. However, they did not undergo such procedures. By analyzing previous treatments, some conditional probabilities were estimated. Considering the previous treatment scheme, 43.8% of the patients who underwent an inadequate previous treatment developed ANS.

Neurosyphilis treatment must be conducted with crystalline penicillin G, since benzathine penicillin G does not achieve therapeutic levels in CSF. Considering that CSF collection was conducted in 14 patients (93.3%) only a year after diagnosis, the lack of past information in the medical records hampered the correct interpretation of the patients’ clinical situation. We wish to note that, during the previous syphilis treatment, none of the patients collected CSF to assess neurosyphilis.

Of the 19 patients that collected CSF, 4 (21.1%) presented detectable viral load values over 40 copies/mL in plasma at the time of CSF collection, suggesting irregular ART use or efficacy failure. Five patients (26.3%) had an CD4LT count < 350 cells/mm³. Two patients (10.5%) showed VDRL reagent in blood with titers ≥1:32 (Table 1). CSF examination revealed altered results in eight patients (42.1%). The individual characteristics of the 19 patients who collected CSF are detailed in Supplementary Table 1. Patient 7 was clinically evaluated and had no history, signs, or symptoms of current disease or history of tuberculosis.

Neurosyphilis can occur at any phase of syphilis, and individuals inadequately treated, especially individuals with coinfection, present less therapeutic efficacy, allowing neurological impairment. T. pallidum invasion of the central nervous system occurs in approximately 40% of patients and is being eliminated in 70% of cases. The use of drugs in inadequate doses and intervals, and the lack of clinical monitoring are two of the main causes of ANS in patients with HIV and syphilis co-infection.

In our study, 73 (21%) patients with HIV and T. pallidum coinfection antecedents at some point of the HIV infection, indicating that regional behavioral factors can enhance the patient’s vulnerability. There has been an increase in PVHIV cases worldwide, as well as of syphilis, and this has influenced the increase of co-infection, with prevalence varying between approximately 9.5%. Of the 73 patients with treponemal test reagent for syphilis, 42.5% were considered cured after treatment and adequate follow-up with negative VDRL. We also observed that, among the 33 patients with treponemal and non-treponemal reagent tests, low income, fertile age, male sex, low schooling, and multiple partners were factors that collaborated with co-infection. These findings are compatible with the HIV epidemiological data in the country, which indicates that this disease, despite seemingly declining in the general population, still increases in these groups. Lack of condom use is also significantly associated with HIV and other STIs.
FIGURE 1: Patient selection flowchart. VDRL: Veneral Disease Research Laboratory; HIV: human immunodeficiency virus; CSF: cerebrospinal fluid.

TABLE 1: Clinical-laboratorial characteristics of the 19 patients with HIV/syphilis co-infection, in Cornélio Procópio, State of Paraná, between 10/01/2018 and 09/30/2019.

| Variables                       | Patients | P-value |
|---------------------------------|----------|---------|
|                                  | n   | %     |
| Time of HIV diagnosis           |      |        |
| < 5 years                       | 9   | 47.4   |
| ≥ 5 years                       | 10  | 52.6   |
| ART use                         |      | <0.001 |
| Yes                             | 18  | 94.7   |
| No                              | 1   | 5.3    |
| Viral Load (copies/mL)          |      | 0.196* |
| ≥ 40                            | 4   | 21.1   |
| < LD                            | 15  | 79.9   |
| CD4LT count (cells/mm³)         |      | 0.251* |
| < 350                           | 5   | 26.3   |
| ≥ 350                           | 14  | 73.7   |
| VDRL (serum)                    |      | <0.001 |
| <1:32                           | 17  | 89.5   |
| ≥ 1:32                          | 2   | 10.5   |
| VDRL (CSF)                      |      | <0.001 |
| NR                              | 18  | 94.7   |
| R                               | 1   | 5.3    |
| Leukocytes (CSF – cells/mm³)    |      | <0.001 |
| < 20                            | 17  | 89.5   |
| ≥ 20                            | 2   | 10.5   |
| Proteins (CSF – mg/dL)          |      | 0.346* |
| < 40                            | 12  | 63.2   |
| ≥ 40                            | 7   | 36.8   |

*Not significant, at a 5% level of significance. ART: antiretroviral therapy; CD4LT: CD4+ T lymphocytes; VDRL: Veneral Disease Research Laboratory; CSF: cerebrospinal fluid; ND: not detectable; LD: lower than the minimum detection limit; NR: not reagent; R: reagent.
With regard to the clinical-epidemiological characteristics, of the 19 patients assessed for ANS, having less than 21 sex partners in life, adequate previous treatment, stable relationship, and heterosexuality showed a low frequency in the development of ANS (Table 2), which can be expected due to the low global prevalence of syphilis (0.5%) and HIV (0.8%)\(^{(15),(16)}\). The mean prevalence of syphilis among sex workers and men who have sex with men is 3.2% and 6%, respectively, which confirms that these behavioral characteristics actually contribute to the development of the disease\(^{(15)}\).

In our study, we verified that the use of illicit drugs is an important factor for HIV and syphilis co-infection, enhancing the chance of neurosyphilis. In a Brazilian study, it was demonstrated that the odds ratio of HIV infection is higher for people exposed to sexual violence at least once in their lifetimes and are under the use of illicit drugs at least once a week, especially crack cocaine. The same study showed that HIV infection was higher in those who presented a reagent treponemic test for syphilis\(^{(14)}\).

In the studied population, we verified that 26.3% of the patients with ANS did not contemplate the national protocol indications for CSF collection at the time of the study. This result indicates a diagnosis loss of neurosyphilis among patients with HIV infection, revealing the fragility of follow-up and vigilance, resulting in the morbidity and mortality of co-infection.

Considering the high patient turnover in reference services, the absence of consultations, frequent treatment abandonment, monitoring, and follow-up are challenging. Moreover, the complexity of the lumbar puncture technique for CSF collection is an obstacle to its realization. In addition, due to frequent domicile changes, many patients do not attend medical appointments with detailed information on syphilis treatment and laboratory monitoring carried out in other services, contributing to a delay in ANS investigation, such as what occurred to patients in this study.

The high prevalence of co-infection at the time of HIV diagnosis was found in our study, and the current epidemic

### TABLE 2: Distribution of the neurosyphilis among the 19 patients with HIV/syphilis co-infection, Cornélio Procópio, State of Paraná, between 10/01/2018 and 09/30/2019.

| Characteristics          | Neurosyphilis |   | Total(%) |
|--------------------------|---------------|---|----------|
|                          | No n(%)       | Yes n(%) |          |
| **Marital status**       |               |   |          |
| Married/Cohabiting       | 6(55)         | 3(38) | 9(47)    |
| Other                    | 5(45)         | 5(62) | 10(53)   |
| Total                    | 11(58)        | 8(42) | 19(100)  |
| **Exposure**             |               |   |          |
| Heterosexual             | 6(55)         | 3(38) | 9(47)    |
| Other                    | 5(45)         | 5(62) | 10(53)   |
| Total                    | 11(58)        | 8(42) | 19(100)  |
| **Partners**             |               |   |          |
| <21                      | 5(45)         | 3(38) | 8(42)    |
| >21                      | 6(55)         | 5(62) | 11(58)   |
| Total                    | 11(58)        | 8(42) | 19(100)  |
| **Licit drugs**          |               |   |          |
| Non-users                | 4(36)         | 4(50) | 8(42)    |
| Users                    | 7(64)         | 4(50) | 11(58)   |
| Total                    | 11(58)        | 8(42) | 19(100)  |
| **Illicit drugs**        |               |   |          |
| Non-users                | 10(91)        | 6(75) | 16(84)   |
| Users                    | 1(09)         | 2(25) | 3(16)    |
| Total                    | 11(58)        | 8(42) | 19(100)  |
| **Previous treatment**   |               |   |          |
| Inadequate, or without history of previous treatment | 9(82) | 7(88) | 16(84) |
| Adequate                 | 2(18)         | 1(12) | 3(16)    |
| Total                    | 11(58)        | 8(42) | 19(100)  |

\(n\): number of patients.
situation of syphilis in Brazil reinforces the necessity of collecting routine outpatient laboratory examinations for the diagnosis of asymptomatic infections.

In individuals with HIV infection, serum VDRL titers $\geq 1:32$ are predictive of neurosyphilis in all individuals with syphilis, while CD4LT count $\geq 350$ cells/mm$^3$ is an additional risk factor for neurosyphilis$^{(8)}$. However, the VDRL test used to assess the CSF sample has a sensitivity variability of 30 to 70%$^{(9)}$.

In our study, we found a 2.3% ANS frequency among patients followed up with SAE. Rotman et al. (2019) retrospectively studied 230 patients with CSF analysis for 10 years in American hospitals and found 70 (8.57%) ANS cases$^{(10)}$. However, we highlight that each country’s context is different, and clinical-epidemiological and social-demographical characteristics are determinants in the development of neurosyphilis.

Lack of outpatient follow-up and examinations in some patients limited CSF collection, resulting in a smaller sample size. Since neurosyphilis notification is not compulsory in Brazil, this hampers a comparative analysis of national data, and does not allow the performance of a historic line and comparison with other comorbidities.

In conclusion, the frequency of ANS found in our study was low, and a significant proportion of these patients did not meet the criteria for lumbar puncture. When we analyzed the patients with a previous history of syphilis treatment, the findings indicated that patients that were adequately treated had a good protective response to neurosyphilis. Thus, clinical-epidemiological and social-demographical variables as predictive factors of ANS should be considered. In addition, detailed information of previous treatment and laboratory follow-up within and between institutions is fundamental for the timely investigation of each case and indication of CSF collection.

ACKNOWLEDGMENTS

We are thankful to the Inter-municipalities Health Consortium of the North of Paraná, and the House of Mercy in Cornélio Procópio, Paraná State.

REFERENCES

1. World Health Organization (WHO). Sexually transmitted infections (STIs) 2019 [Internet]. Global health sector strategy on sexually transmitted infections. [Update 2016–2021, cited 2021 May 1]. Available from: https://www.who.int/en/news-room/fact-sheets/detail/sexually-transmitted-infections-(stis).

2. Lee HC, Ko NY, Lee NY, Chang CM, Liu SY, Ko WC. Trends in sexually transmitted diseases and risky behaviors among HIV-infected patients at an outpatient clinic in southern Taiwan. Sex Transm Dis. 2010;37(2):86-93.

3. Kalichman SC, Pellowski J, Turner C. Prevalence of sexually transmitted co-infections in people living with HIV/AIDS: systematic review with implications for using HIV treatments for prevention. Sex Transm Infect. 2011;87(3):183-90.

4. Rotman L, Luo X, Thompson A, Mackesy-Amith ME, Young LR, Young JD. Risk of neurosyphilis in HIV-infected persons with syphilis lacking signs or symptoms of central nervous system infection. HIV Med. 2019;20(1):27-32.

5. Workowski KA, Bolan GA. Sexually transmitted diseases treatment guidelines, 2015. MMWR Recomm Rep. 2015;64(RR-03):1-137.

6. Ministério da Saúde (MS). Secretaria de Vigilância em Saúde. Departamento de DST, AIDS e Hepatites Virais. Protocolo Clínico e Diretrizes Terapêuticas (PCDT) Atenção Integral às Pessoas com Infecções Sexualmente Transmissíveis (IST), 2019. 1ª edição. Brasília: MS, 2020. 248 p.

7. Janier M, Hegyi V, Dupin N, Unemo M, Tiplica GS, Potocnik M, et al. 2014 European guideline on the management of syphilis. J Eu Acad Dermatol Venereol. 2014;28(12):1581-93.

8. Marra CM, Maxwell CL, Smith SL, Lukehart SA, Rompalo AM, Eaton M, et al. Cerebrospinal fluid abnormalities in patients with syphilis: association with clinical and laboratory features. J Infect Dis. 2004;189(3):369-76.

9. M Marks, D Lawrence, C Kositz, D Mabey. Diagnostic performance of PCR assays for the diagnosis of neurosyphilis: a systematic review. Sex Transm Infect. 2018;94(8):1-4.

10. Marra CM. Neurosyphilis. Continuum (Minneapolis Minn). 2015;21(6 Neuroinfectious Disease):1714-28. Available from:https://doi.org/10.1212/CON.00000000000000250.

11. Lukehart SA, Hook EW, 3rd, Baker-Zander SA, Collier AC, Critchlow CW, Handsfield HH. Invasion of the central nervous system by Treponema pallidum: implications for diagnosis and treatment. Ann Intern Med. 1988;109(11):855-62.

12. UNAIDS. Estatísticas 2020 - UNAIDS Brasil. 2020 [Internet]. [Cited 2021 May 1]. Available from: https://unaids.org.br/estatisticas/?gclid=Cj0KCQAvJXxBrCeARi5kAqpwZg5jBTnb_Md1VYDaw8Zk9yHL58k5yRfso7F84XOSTW-DHWyWyaAqRBEALw_wcB.

13. Ministério da Saúde (MS). Secretaria de Vigilância em Saúde. Departamento de Vigilância, Prevenção e Controle das Infecções Sexualmente Transmissíveis, do HIV/Aids e das Hepatites Virais. Boletim Epidemiológico de HIV/Aids. 2020. 2020 [Available from: http://www.aids.gov.br/pt-br/pub/2020/boletim-epidemiologico-hivaids-2020].

14. Szowarcwald CL, Damacena GN, de Souza-Júnior PRB, Guimarães MDC, de Almeida Wda S, de Souza Ferreira AP, et al. Factors associated with HIV infection among female sex workers in Brazil. Medicine (Baltimore). 2018;97(1 Suppl).

15. Rowley J, Vander Hoorn S, Korenromp E, Low N, Unemo M, Abu-Raddad LJ, et al. Chlamydia, gonorrhoea, trichomoniasis and syphilis: global prevalence and incidence estimates, 2016. Bull World Health Organ. 2019;97(8):548-62p.

16. World Health Organization (WHO). Prevalence of HIV among adults aged 15 to 49 Estimates by WHO region 2019 [Internet]. [Cited 2021 May 1]. Available from: http://apps.who.int/gho/data/view.main.22500WHOREG?lang=en.

Received 14 July 2021 | Accepted 8 October 2021
**SUPPLEMENTARY TABLE 1**: General characteristics of the 19 HIV/syphilis co-infected patients that collected CSF, in Cornélio Procópio, State of Paraná, between 10/01/2018 and 09/30/2019.

| Patient | HIV Previous syphilis treatment | Viral load (copies/mL) | CD4LT (cells/mm³) | VDRL (serum) | VDRL (CSF) | Leukocytes (CSF) (leuk./mm³) | Proteins (CSF) (mg/dL) | Red cells (CSF) (cells/mm³) | ANS | CPTG’S crítéria for CSF collection |
|---------|---------------------------------|------------------------|-------------------|--------------|------------|-------------------------------|-----------------------|----------------------------|-----|----------------------------------|
| 1       | IT                              | 90                     | 452               | 1/4          | NR         | 3                             | 31.1                  | 0                          | No  | No                               |
| 2       | AT                              | ND                     | 260               | 1/8          | NR         | 5                             | 9                     | 12                         | No  | Yes                             |
| 3       | IT                              | <min lim               | 1,090             | 1/16         | NR         | 3                             | 10.8                  | 165                        | No  | No                               |
| 4       | NT                              | 17,705                 | 217               | 1/16         | NR         | 4                             | 46.7                  | 10                         | Yes | Yes                             |
| 5       | IT                              | ND                     | 449               | 1/4          | NR         | 8                             | 61                    | 14                         | Yes | No                               |
| 6       | IT                              | ND                     | 565               | 1/2          | NR         | 2                             | 48.5                  | 73                         | Yes | No                               |
| 7       | NT                              | ND                     | 120               | 1/32         | NR         | 38                            | 175.3                 | 0                          | Yes | Yes                             |
| 8       | IT                              | ND                     | 798               | 1/16         | NR         | 2                             | 11.1                  | 0                          | No  | No                               |
| 9       | AT                              | 25,458                 | 208               | 1/64         | 1/1        | 13                            | 46.5                  | 0                          | Yes | Yes                             |
| 10      | AT                              | <min lim               | 589               | 1/8          | NR         | 1                             | 12.4                  | 4                          | No  | No                               |
| 11      | NT                              | <min lim               | 283               | 1/4          | NR         | 5                             | 33.7                  | 7                          | No  | Yes                             |
| 12      | NT                              | ND                     | 1021              | 1/4          | NR         | 1                             | 30.2                  | 5                          | No  | No                               |
| 13      | IT                              | <min lim               | 1244              | 1/8          | NR         | 2                             | 17.8                  | 0                          | No  | No                               |
| 14      | AT                              | ND                     | 412               | 1/16         | NR         | 2                             | 12.5                  | 0                          | No  | No                               |
| 15      | IT                              | ND                     | 390               | 1/2          | NR         | 6                             | 49.9                  | 1                          | Yes | No                               |
| 16      | IT                              | ND                     | 492               | 1/2          | NR         | 1                             | 17                    | 0                          | No  | No                               |
| 17      | IT                              | ND                     | 537               | 1/2          | NR         | 85                            | 35                    | 2                          | Yes | No                               |
| 18      | IT                              | <min lim               | 409               | 1/4          | NR         | 0                             | 40.7                  | 1                          | Yes | No                               |
| 19      | IT                              | 261                    | 897               | 1/4          | NR         | 3                             | 30.9                  | 126                        | No  | No                               |

**HIV**: human immunodeficiency virus; **AT**: adequate previous treatment and laboratorial monitoring for syphilis; **IT**: inadequate previous treatment and laboratorial monitoring for syphilis; **NT**: no syphilis treatment before the research; **CD4LT**: CD4+ T lymphocytes; **VDRL**: Veneral Disease Research Laboratory; **CSF**: cerebrospinal fluid; **ND**: not detectable; **< min lim**: lower than the minimum detection limit; **NR**: not reagent; **ANS**: asymptomatic neurosyphilis; **CPTG**: Clinical Protocol and Therapeutic Guidelines.